

Requested Patent: WO03055536A1

Title: A WOUND CARE DEVICE ;

Abstracted Patent: WO03055536 ;

Publication Date: 2003-07-10 ;

Inventor(s):

STERM LARSEN TRUELS (DK); JUEL-FRIIS GITTE (DK); RICHTER-FRIIS TINE (DK)

Applicant(s):

STERM LARSEN TRUELS (DK); COLOPLAST AS (DK); JUEL-FRIIS GITTE (DK);  
RICHTER-FRIIS TINE (DK) ;

Application Number: WO2002DK00884 20021219 ;

Priority Number(s): DK20010001942 20011221 ;

IPC Classification: A61L15/44; A61L26/00 ;

Equivalents: ;

ABSTRACT:

A wound care device for local treatment of pain in a wound comprising an active pain relieving composition, wherein said composition is an anti-inflammatory pain killing agent. The wound care device is suitable for treatment of pain in open wounds. The device may be in the form of a wound dressing, and the pain relieving composition may be delivered to the wound through a controlled release system.

**TITLE**

A wound care device

**FIELD OF THE INVENTION**

- 5 This invention relates to wound care devices comprising an active pain-relieving agent for local pain relief in an open wound setting and a method of treating pain in such wounds.

**BACKGROUND OF THE INVENTION**

- 10 It is widely recognised that wound pain is one of the major problems associated with wounds or ulcers. Wounds are by definition divided into two categories: Acute and chronic wounds. Acute wounds may be wounds such as burns and surgical wounds, while chronic wounds may be in the form of pressure sores, leg ulcers and diabetic ulcers. Pain can be associated with both chronic and acute  
15 wounds although the influence on patients well-being will be more pronounced when the wound is chronic.

- Pain can be divided into three categories: Acute pain, non-malignant pain and cancer pain. Wound pain will often be either acute or non-malignant dependent  
20 on the character of the actual wound and whether the wound is being manipulated or not e.g. during a dressing change. Furthermore, the pain will in general have nociceptive or neurogen origin.

The actual kind of wound pain can be divided into three classes:

- 25 - Non-cyclic acute wound pain, which may occur during for instance at debridement of necrotic tissue in a wound or removal of drainage.  
-Cyclic acute wound pain, which may occur during for instance dressing changes or in some cases debridement.  
-Chronic wound pain, which is a persistent pain that occur even without manipulation of the involved skin or tissue, i.e. pain between dressing changes.  
30

In the following we will primarily address relief of the persistent pain or the chronic pain associated with wounds between dressing changes. However,

treatments suitable for this purpose may also be able to relieve pain during dressing change and debridement as described below.

Pain in itself is of course a major discomfort for the patient and will therefore affect patients quality of life. In addition, pain stimulates catecholamine release and as a result of that local vasoconstriction arises and a reduced oxygen supply to a cutaneous wound will occur. This may affect wound healing and resistance to infection of the wound. Furthermore, wound healing may also be delayed due to the general influence pain may have on the patient, such as loss of appetite, less mobility, worse overall condition and lack of enthusiasm. However, the possible effect of pain on wound healing has not been proven in the literature and is therefore speculative. In contrast, it is well recognized that pain has an impact on the health related quality of life (HQoL) for patients.

Wound pain has proven to be decreased by modern moist wound healing principles. Moist wound healing dressings keep the environment under the dressing moist but are at the same time capable of absorbing considerable amounts of exudate from the wound, in order to protect the periulcer skin and to avoid leakage. During the wear time of a moist wound healing dressing, tissue and nerve endings remain moist. Such dressings, e.g. hydrocolloid dressings will be soothing and less painful than traditional dry gauze dressings during application and in situ. Debridement will often also be less painful as the wound bed will be kept in a moist condition and thus no painful drying out is seen.

Although moist wound healing has been proven to improve healing rates, relieve pain in situ, prevent the wound bed from drying out, decrease the discomfort with wound debridement and overall improve the quality of life for the patient, added benefits in terms of a more direct way of addressing the local wound pain between dressing changes associated with wounds are still needed.

30

It is well known in the art to incorporate analgesics or anaesthetics into topical products for treatment of pain or to produce anaesthesia in intact skin surfaces or systemically in the body. These products may be in the form of trans-dermal dressings or patches, creams, gels or ointments. In order to enhance the rate at

which the drug passes through the skin to reach the systemic circulation from e.g. the trans-dermal patch or to achieve an appropriate formulation for intact skin surfaces it is often desirable or even necessary to incorporate other components. These components will interfere with an open wound setting in terms of producing possible irritation, sensitisation or even toxicological effects in the open wound setting and to the often very fragile periwound skin around the open wound.

In International Patent Application No. WO 94/23713 is disclosed a trans-dermal anti-inflammatory compositions. The compositions may be used for topical and trans-dermal application, such as ointments and dressings and the anti-inflammatory composition is preferably NSAIDs (non-steroid anti-inflammatory drugs).

However, delivering drugs to intact healthy skin and to the systemic circulation is very different from delivering drugs locally to open wounds or damaged skin. The skin provides an effective barrier between the drug and the underlying tissue and blood circulation in trans-dermal delivery, and therefore, the drug has to be formulated in such a way that it is capable of overcoming this barrier. Also the concentration of the drug in the trans-dermal formulation has to be higher in order to overcome the skin barrier and reach the systemic circulation in a plasma concentration high enough for systemic effect. A wound is provided with little or no barrier, and furthermore, the wound will often exudate and may be contaminated.

Furthermore, a wound dressing often needs to be provided with wound exudates handling means in order to give optimal comfort for the patient. The barrier for the release of the drug for local use in an open wound will be the medical device and not the intact skin. The medical device may absorb and retain the exudate from the wound and therefore prevent maceration of the surrounding skin and the wound tissue that is often fragile and vulnerable. As a result the wound management and patient comfort is increased. A trans-dermal patch or a topical cream or ointment will not be able to handle wound exudate and neither the adhesive nor the other components of the patch may be designed to an open wound setting and to contact with the very fragile skin surroundings. Also the drug concentration

in a trans-dermal system or a topical ointment, gel or cream may be too high to be used in an open wound where no absorption barrier is seen. Furthermore, additives such as penetration enhancers comprised in the creams, gels or ointments or trans-dermal patches will make them unsuitable for use in an open wound, as  
5 these additives often are too aggressive or even toxic for introducing directly into an open wound.

Most wound care products are prepared without such additives as these additives may interfere with the wound healing and influence the well being of the patient. Examples are hydrogels made especially for e.g. debridement in open  
10 wounds and for application under a dressing and other devices for moist wound healing like dressings comprising foams, alginates or hydrocolloids.

A controlled release of drugs is often desired both in trans-dermal delivery and  
15 open wound treatment. However, the release mechanisms may be quite different in the two systems. In a trans-dermal device such as a patch, cream, ointment or gel, the skin barrier may serve as the controlling release layer. The additives may further control the release. In a wound care device, the release may be controlled in other ways, e.g. by the amount of exudate from the wound, or by using con-  
20 trolled release matrices.

Analgesics in a broad term can relieve pain in open wounds without seriously interfering with the sense perception. In contrast, anaesthetics interfere with sense perception when applied locally, and can result in loss of consciousness when  
25 used centrally. Loss of sense perception in a wound and surroundings is considered to be irrationally and inconvenient since the patient loses the ability to feel possible injury and change in the wound. Therefore it may be preferred to use analgesics in order to relieve wound pain over a longer period.

30 In US Patent No. 6,312,713 is disclosed a thin-layered dressing for surface wounds which gradually releases drugs, such as analgesics. The drug is incorporated in a hydrophilic polymeric matrix and may be used topically. The dressing is thin and does not comprise wound exudates handling means, and will thus only be suitable for dry wounds.

US Patent No. 5,792,469 a in situ forming film dressing with therapeutic agents such as pain relieving agents. The film is sprayed onto the desired body part. The dressing is only suitable for dry wounds, as no wound exudates handling means  
5 are included.

In US Patent No. 6,048,850 is disclosed a method of selectively inhibiting PGHS-2 in a human host. The reference is silent with respect to local wound treatment.

10 US Patent No. 6,190,689 discloses a trans-dermal device comprising a hot-melt adhesive with an incorporated substance. The use of pain relieving agents in the treatment of wounds is mentioned, but the reference is silent with respect to any details or examples to this subject.

15 In International Patent Application No. WO 00/07574 is disclosed medicinal products with retarded pharmacological activity. The products are primarily intended for use in catheters, though use in wound care devices is mentioned.

Thus, there is still a need for a medical device addressing superior wound management as well as local pain relief in terms of addition of analgesic compounds.  
20 Such a wound care device is achieved by the present invention combining the beneficial effects of moist wound healing with the pharmacological effects of a pain relieving agent, that supply pain relief locally to a wound and nearby surroundings but not systemically i.e. in the body.

25

#### **BRIEF DESCRIPTION OF THE INVENTION**

The present invention relates to a wound care device for treatment of pain in a wound comprising an active pain relieving composition.

30 The invention further relates to a method of treating pain at a wound site.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention relates to a wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, said

composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the device is below the systemic or topical daily unit dose for systemic treatment using the agent.

- 5 In one embodiment of the invention the amount of pain killing agent is less than 75% of the systemic or topical daily unit dose for systemic treatment using the agent.

In another embodiment of the invention the amount of pain killing agent is less  
10 than 50% of the systemic or topical daily unit dose for systemic treatment using the agent.

It may be preferred that the amount of pain killing agent is less than 25% of the systemic or topical daily unit dose for systemic treatment using the agent.

15

It is even more preferred that the amount of pain killing agent is less than 10% of the systemic or topical daily unit dose for systemic treatment using the agent.

In one embodiment of the invention the amount of pain killing agent is less than  
20 5% of the systemic or topical daily unit dose for systemic treatment using the agent.

When addressing the systemic or topical daily unit dose for systemic treatment for a pain killing agent is meant the daily dose for achieving a systemic pain reliev-  
25 ing effect, i.e. achieving a desired plasma concentration.

In Table 1 is shown examples of systemic or topical daily unit doses of various pain killing agents. Examples are shown below in the range of normally recommended use for adults:

30

TABLE 1

| Drug                 | Systemic daily unit dose | Topical daily unit dose |
|----------------------|--------------------------|-------------------------|
| Naproxen             | 200 – 500 mg             | Not available           |
| Ketoprofen           | 100 – 300 mg             | 375 mg                  |
| Piroxicam            | 10 – 20 mg               | 25 mg                   |
| Ibuprofen            | 1200 – 2400 mg           | 500 – 800 mg            |
| Celecoxib            | 200 – 400 mg             | Not available           |
| Acetylsalicylic acid | 2 – 4 g                  | Not available           |
| Indomethacin         | 150 – 200 mg             | Not available           |
| Acetaminophen        | 2 – 4 g                  | Not available           |
| Diclofenac           | 150 – 200 mg             | Not available           |

The present invention discloses an approach for formulating a moist wound healing device with improved pain relieving properties. The moist wound healing principles offers a passive pain relieving effect by keeping the wound moist. The addition of an active pain relieving composition to the wound care device further improves the capability of the device of relieving wound pain especially the persistent pain or chronic pain between dressing changes.

The analgesics in the device of the invention may be released over time locally to the wound. Preferably, the release of the pain relieving composition is so low that no systemic effect is seen. Thus, the concentration of analgesics in the device of the invention may be so low that little or no effective systemic plasma concentration can be found. This will reduce or even eliminate the possible systemic side effects of the analgesics, and at the same time provide the patient with maximum safety, as oral doses or topical doses on intact skin can be taken at the same time. Thus, the device renders it possible to ingest additional medication, if needed, orally or topically of the same type as in the wound care device, without the risk of overdosing. Furthermore, side effects are lowered and compliance will be better as well as the HQoL.

For different analgesics, the plasma concentration for systemic effect in the lowest range is reported to be as follows given as examples: Acetylsalicylic acid:



270 µg/ml ; Ketoprofen: 3 µg/ml; Ibuprofen: 10 µg/ml; Piroxicam: 1 µg/ml. Thus, a wound care device for treatment of pain in a wound releasing analgesics locally to a wound site may be designed in such a way that the plasma concentration is under the lowest range for systemic effect in the body.

5

This is also true for other anti-inflammatory pain relieving compositions being suitable for incorporation into medical devices combining wound exudates handling means and local treatment of wound pain in open wounds.

- 10 It is widely held that anti-inflammatory pain killing agents, such as NSAIDS, are unsuitable for use in open wound settings. The compositions are primarily used for treatment of systemic diseases, not for local treatment. It is further believed that the compositions may cause local irritation, as well as it has been recommended to avoid use of such compositions in open wounds.

15

It has surprisingly been found that by incorporating an anti-inflammatory pain killing agent in a wound care device, a local pain-relieving effect in an open wound is achieved. Local side effects have surprisingly not been seen as well as the plasma concentrations, if any, of the agent were below the concentrations for  
20 systemic effect.

The device according to the present invention is primarily intended for use as local pain relief. When a systemic effect of the pain-relieving agent is desired e.g. when providing pain relief against rheumatoid arthritis, muscle pain or head-  
25 aches, orally ingested analgesics may be preferred. The pain relieving composition of the device of the invention may be applied to damaged skin locally and directly onto an open wound without interfering with the wound healing.

- Prostaglandins, leukotrienes, and thromboxanes are key inflammatory mediators  
30 produced from arachidonic acid. Inhibition of the synthesis of these mediators is the target of the most highly prevalent class of anti-inflammatory drugs, the NSAIDs. Inflammatory mediators will stimulate pain nociceptors and as a result pain is produced.

Pain impulses in skin tissue arise from pain receptors in the skin and deeper structures. The intensity of the pain increases when the number of receptors activated and the frequency of impulses increase. The perception of pain in e.g. peripheral tissue such as the skin begins with stimulation of nerve fibres called nociceptors. In a process called transduction, a nociceptive stimulus makes nociceptor membranes permeable to sodium ions. In a second process known as transmission, the influx of sodium ions sends a signal to the dorsal horn of the spinal cord. In a third process, modulation, systems that inhibit and facilitate pain act on the generated signals. Finally in the perception process a factor called plasticity, which is based in part on prior experienced pain, determines how intensely the pain is perceived. Pain is therefore also subjective. It has both a psychological and physiological component. Acute, and social, cultural and psychological factors affect it. The feeling of pain is protective in situations where it alerts the body of actual or potential damage. Beyond these situations its function is less clear.

Inflammatory pain is believed to be important for the actually feeling of chronic or persistent wound pain. It is believed that tissue injury as e.g. seen in chronic wounds triggers the release of multiple inflammatory mediators that themselves, alter nociceptor function. The level of inflammation is therefore elevated and may be lowered by addition of anti-inflammatory drugs locally to the wound that would lead to pain relief.

Preferably the pain relieving composition comprises an anti-inflammatory painkilling agent that blocks the production of inflammatory mediators produced from arachidonic acid.

NSAIDs (non-steroid anti-inflammatory drugs) generally have analgesics and antipyretic properties along with their anti-inflammatory capabilities. Anti-inflammatory pain killing agents interact with enzyme targets such as cyclooxygenase-inhibiting NSAIDs. The enzymes PGHS (prostaglandin H synthase), commonly known as COX (cyclooxygenase), is responsible for processing arachidonic acid into inflammatory mediators. COX comes from two isoforms COX 1 and COX 2. COX 1 is produced in a more or less constant level at all times and is

or Phenacetin, Non-acid derivatives Nabumeton, Coxib derivatives such as Celecoxib or Rofecoxib.

Compounds inhibiting COX 2 specifically may be Coxib derivatives such as Celecoxib or Rofecoxib.

In one embodiment of the invention the pain relieving composition is Ibuprofen.

In another embodiment of the invention the pain relieving composition is Ketoprofen.

The pain relieving composition may be incorporated as particles, coated particles or diluted in constituent phases of the medical device or distributed in an aiding agent therein.

15

The particles may be mixed with one or more of the constituents of the wound care device, such as the particles may be incorporated into an adhesive, an absorbent layer or they may be incorporated in a film.

20 The pain relieving composition may be dissolved or suspended in one or more of constituents of the wound care device or alternatively in one or more constituents acting as precursor material for the constituent.

In one embodiment of the invention the particles may be dissolved in an aiding vehicle in the form of a liquid or solid and may appear as a discrete phase in one or more of the components of the device, e.g. a water insoluble composition may be incorporated into an hydrophobic vehicle or vice versa.

The wound care device may further comprise a controlled release system.

30

The pain relieving effect of the device according to the invention is over time originated from release of the pain killing agent to the wound. When studying a dressing that has been applied over an open wound for a period, the pain killing agent diminish or disappear in the area directly over the wound due to a release

to the wound, while a negligible amount will be released in the area over the periwound skin.

In one embodiment of the invention the release may be controlled as a function  
5 of the amount of a selected constituent of the wound exudate.

In a preferred embodiment of the invention the selected constituent is liquid.

The pain relieving composition may be released to the wound by controlled re-  
10 lease locally in relation to the amount of wound exudate absorbed and retained in the medical device and further delayed by coating the pain relieving agent or incorporating it into a vehicle.

In one embodiment of the invention the pain relieving component may be in the  
15 form of coated particles with controlled release properties. The coating may be any suitable coating known in the art of release systems providing the particles with the desired release properties. An example may be Ketoprofen particles coated with an Eudragit grade.

20 Preferably, the device of the invention is in the form of a wound dressing, or a part of a wound dressing.

The dressing may be in the form of a single unit or a layered product.

25 The device may comprise wound exudate absorbing means.

The dressing of the invention may comprise an absorbing constituent or element. The pain relieving composition may be comprised in such absorbing constituent or element as wound exudate or other liquid will then more easily be brought into  
30 contact with the pain relieving composition.

An absorbing constituent or element may preferably be a separate element of an absorbing foam, a hydrogel, or paste, hydro-sheet or be in the form of hydrocol-

loids and/or an alginate in the form of a separate element or particulate and homogeneously distributed in the dressing.

In one embodiment of the invention the absorbing element comprises foam, preferably polyurethane foam.

Such an absorbing element may in one embodiment constitute a dressing of the invention. In such case, the absorbing element may in itself show adhesive properties or it may not show adhesive properties and it will then typically be secured to the desired site using conventional means such as a cover dressing.

The device of the invention may comprise an adhesive.

The device of the invention may comprise a skin-contacting surface comprising an area showing a skin friendly adhesive.

Such a dressing may suitably be a dressing comprising a substantially water-impervious layer or film and a skin-friendly adhesive in which an absorbing constituent or element is incorporated.

20

The skin-friendly adhesive may be any skin-friendly adhesive known per se, e.g. an adhesive comprising hydrocolloids or other moisture absorbing constituents such as the adhesives disclosed in US patent No. 4,231,369 and in US patent No. 4,367,732 comprising hydrocolloids. A dressing comprising a separate absorbing element may e.g. be of the type disclosed in US Patent No. 5,051,259 or 5,714,225.

A water impervious layer or film may be of any suitable material known per se for use in the preparation of wound dressings e.g. a foam, a non-woven layer or a polyurethane, polyethylene, polyester or polyamide film. A suitable material for use as a water impervious film is a polyurethane such as the low friction film material is disclosed in US patent No. 5,643,187.

In another embodiment of the invention the device may be a wound cavity filler. The cavity filler may e.g. be in the form of fibres, gel or hydrogel, foam or powder.

The device of the invention may further comprise one or more active ingredients  
5 besides the pain killing agent.

The wound care device according to the invention may comprise one or more active ingredients, e.g. a pharmaceutical medicament. Examples of such pharmaceutical medicaments such as bacteriostatic or bactericidal compounds, e.g. iodine, iodopovidone complexes, chloramine, chlorhexidine, silver salts such as  
10 sulphadiazine, silver nitrate, silver acetate, silver lactate, silver sulphate, silver sodium thiosulphate or silver chloride, zinc or salts thereof, metronidazol, sulpha drugs, and penicillin's, tissue-healing enhancing agents, e.g. RGD tripeptides and the like, proteins, amino acids such as taurine, vitamins such as ascorbic acid, enzymes for cleansing of wounds, e.g. pepsin, trypsin and the like, proteinase inhibitors or metalloproteinase inhibitors such as Illostat or ethylene diamine tetraacetic acid, cytotoxic agents and proliferation inhibitors for use in for example surgical insertion of the product in cancer tissue and/or other therapeutic agents which optionally may be used for topical application, emollients, retinoids  
20 or agents having a cooling effect which is also considered an aspect of the invention.

The active ingredient may also comprise odour controlling or odour reducing material such as charcoal.

25

The invention further relates to a method of treating pain at a wound site comprising applying to the wound a wound care device comprising an active pain relieving composition.

30 The pain relieving composition may preferably be an anti-inflammatory pain relieving composition, said composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the device is below the daily unit dose for systemic treatment or daily unit dose for topical treatment using the agent.

When applying a wound care device according to the invention to a wound, the pain relieving composition will be released to the wound bed, and pain relief is achieved. Preferably the pain relieving composition will be released over a period of time, in order to provide a controlled or sustained release of the composition.

- 5 Thus, a prolonged wear time of the dressing is achieved, rendering it possible to avoid frequent dressing changes. Change of dressings is often associated with pain, hence a low frequency of dressing changes is desired.

## EXAMPLES

### 10 EXAMPLE 1

Preparation of a foam dressing

- A polyurethane foam was prepared in the following way: 100 parts w/w Hypol2002 (Dow Chemical Company) were mixed with 1 part w/w Pluronic 62 (BASF), 100 parts w/w of water and an amount of the pain killing agent as specified in the following examples. The materials were mixed together for approximately 15 seconds. The liquid was poured into a mould and allowed to react for 10 minutes. The resulting foam sheet was dried in an oven at 70°C for 30 minutes, and cut into 20 x 20 cm dressings with a thickness of 4,4 mm. The device  
20 may further be sterilized using gamma radiation.

### EXAMPLE 2

Foam dressing containing Ibuprofen

- 25 A foam dressing was prepared as described in Example 1 with 1 part w/w Ibuprofen.

### EXAMPLE 3

Foam dressing containing piroxicam

30

A foam dressing was prepared as described in Example 1 with 0.04 part w/w piroxicam.

**EXAMPLE 4****Foam dressing containing ketoprofen**

A foam dressing was prepared as described in Example 1 with 0.06 part w/w ketoprofen.

**EXAMPLE 5****Preparation of a hydrocolloid dressing**

A hydrocolloid adhesive was prepared from the following ingredients as described in US Pat. No. 4,231,369: 25,1% Kraton D 1107 (Shell Chemical Company), 35,1% Arkon P90 (Arakawa Chemical), 30% Carboxy methyl cellulose, 8,8% dioctyladipat, 1% antioxidant (methylene-bis -4 methyl 6 t-butylphenol). The adhesive was coated in a layer of 1,1 mm on a polyurethane film, and the resulting laminate was cut into dressings with a size of 20 x 20 cm. The dressings were preferably sterilized by gamma irradiation.

**EXAMPLE 6****Hydrocolloid dressing containing Ibuprofen**

20

A hydrocolloid dressing was prepared as described in Example 5 containing 97.8 % w/w of the recipe and 2.2 % w/w Ibuprofen was added.

**EXAMPLE 7**25 **Hydrocolloid dressing containing Piroxicam**

A hydrocolloid dressing was prepared as described in Example 5 containing 99.96 % w/w of the recipe and 0.04 % w/w Piroxicam was added.

30 **EXAMPLE 8****Hydrocolloid dressing containing Ketoprofen**

A hydrocolloid dressing was prepared as described in Example 5 containing 99.6 % w/w of the recipe and 0.4 w/w Ketoprofen was added.



**EXAMPLE 9****Preparation of a hydrogel**

- 5 A water containing hydrogen comprising the following ingredients was prepared:  
96% w/w water, 3.6% w/w Aquasorb, 0.4% w/w Calcium alginate. About 2/3 of the  
water was added to a mixer. Calcium alginate and the pain killing agent was  
mixed, and thereafter 1/4 of the Aquasorb was added first, followed by the rest of  
the Aquasorb. This mixture was slowly added to the water and mixed further.
- 10 When the phase was homogenous, the rest of the water was added slowly with  
continuous mixing for at least 20 minutes. The gel may be sterilized using an  
autoclave.

**EXAMPLE 10**

- 15 Preparation of a hydrogel containing Ketoprofen

A hydrogel was prepared as described in Example 9 containing 99.9 % w/w of  
the recipe and 0.1 % w/w Ketoprofen.

- 20 **EXAMPLE 11**

**Preparation of a hydrogel containing Ibuprofen**

A hydrogel was prepared as described in Example 9 containing 98 – 99.5 % w/w  
of the recipe and 0.5 – 2.0 % w/w Ibuprofen.

25

**EXAMPLE 12****Preparation of a hydrogel containing Piroxicam**

- A hydrogel was prepared as described in Example 9 containing 99.9 % w/w of  
30 the recipe and 0.1 % w/w Piroxicam.

**EXAMPLE 13****Use of a dressing according to the present invention**

A foam dressing as described in Example 1 and 2 was applied to patients with venous ulceration. The patients were treated for 10 days, with change of the dressing every second day. Very good local pain relief and a convincing reduction of the pain intensity during wear time of the dressing were reported. No local  
5 side effects as well as systemic side effects were observed. Plasma concentrations were monitored closely. No levels for systemic effect was found in plasma. Further it was shown that wound healing progressed according to expectations i.e. no delay in wound healing was observed. A very convincing improvement in HQoL was seen during the treatment time.

**CLAIMS**

1. A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, said composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the  
5 device is below the daily unit dose for systemic treatment or daily unit dose for topical treatment using the agent.

2. A device according to claim 1, wherein the device comprises wound exudates absorbing means.

10

3. A device according to claim 1 or 2, wherein the amount of pain killing agent is less than 75% of the daily unit dose for systemic treatment or daily unit dose for topical treatment using the agent.

15 4. A device according to any of claim 1-3, wherein the amount of pain killing agent is less than 50% of the daily unit dose for systemic treatment or daily unit dose for topical treatment using the agent.

5. A device according to any of claims 1-4, wherein the pain relieving composition  
20 is capable of inhibiting mediators responsible for processing arachidonic acid into inflammatory mediators.

6. A device according to any of claims 1-5, wherein the pain relieving composition is capable of inhibiting COX 1 and COX 2.

25

7. A device according to any of claims 1-6, wherein the pain relieving composition comprises one or more compounds chosen from the group of Phenylpropionic acids, Phenylacetic acids, Indoleacetic acids, Pyrroleacetic acids, N-Phenylacetic acids, Salicylates, Enolic acids, Phenols, Non-acids or Coxibs.

30

8. A device according to any of claims 1-7 wherein the pain relieving composition is incorporated as particles, coated particles or diluted in constituent phases of the medical device or distributed in an aiding agent therein.

9. A device according to any of claims 1-8 wherein the device further comprises a controlled release system.

10. A device according to claim 9 wherein the release is controlled as a function  
5 of the amount of a selected constituent of wound exudate.

11. A device according to claim 10 wherein the selected constituent is liquid.

12. A method of treating pain at a wound site comprising applying to the wound a  
10 wound care device comprising an active pain relieving composition, said composition is an anti-inflammatory pain killing agent, wherein the amount of pain killing agent in the device is below the daily unit dose for systemic treatment or daily unit dose for topical treatment using the agent.

## INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/DK 02/00884

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L15/44 A61L26/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | WO 00 02539 A (LOHMANN THERAPIE SYST LTS<br>;MUELLER WALTER (DE))<br>20 January 2000 (2000-01-20)<br>claims   | 1-12                  |
| X          | WO 01 80797 A (HYSON MORTON I)<br>1 November 2001 (2001-11-01)<br>page 10, line 12 - line 35<br>page 11, line 1 - line 3  | 1-12                  |
| X          | WO 98 22114 A (NICOLAJSEN HENRIK VIGAN<br>;DUMEX LTD AS (DK); MOESS JUDI (DK);<br>JORGE) 28 May 1998 (1998-05-28)<br>page 29, line 29 - line 32<br>page 30 -page 31 | 1-12                  |
|            | -/-   |                       |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

2 April 2003

Date of mailing of the international search report

14/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

ESPINOSA, M

## INTERNATIONAL SEARCH REPORT

Internat Application No  
PCT/DK 02/00884

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | US 5 719 197 A (KANIOS DAVID P ET AL)<br>17 February 1998 (1998-02-17)<br>column 21, line 51 - line 67<br>column 22, line 1 - line 18<br>----- | 1-12                  |
| X          | US 6 190 690 B1 (CHOI JAE-KEUN ET AL)<br>20 February 2001 (2001-02-20)<br>claims<br>-----  | 1-12                  |
| X          | US 6 312 713 B1 (KOROL BERNARD ET AL)<br>6 November 2001 (2001-11-06)<br>cited in the application<br>column 13, line 22 - line 23<br>-----     | 1-12                  |
| X          | GB 2 311 027 A (JOHNSON & JOHNSON MEDICAL)<br>17 September 1997 (1997-09-17)<br>page 4, line 11 - line 12<br>-----                             | 1-12                  |
| X          | US 5 792 469 A (DUNN RICHARD L ET AL)<br>11 August 1998 (1998-08-11)<br>cited in the application<br>column 9, line 41 - line 44<br>-----       | 1-12                  |
| X          | US 5 993 849 A (KAEHLER STEPHANIE ET AL)<br>30 November 1999 (1999-11-30)<br>claims<br>-----   | 1-12                  |

# INTERNATIONAL SEARCH REPORT

Int'l application No.  
PCT/DK 02/00884

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
on patent family members

International Application No  
**PCT/UK 02/00884**

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| WO 0002539                                | A | 20-01-2000          | DE 19830649 A1             | 13-01-2000          |
|   |   |                     | AU 750861 B2               | 01-08-2002          |
|   |   |                     | AU 4907599 A               | 01-02-2000          |
|   |   |                     | BR 9911981 A               | 27-03-2001          |
|   |   |                     | CA 2336732 A1              | 20-01-2000          |
|   |   |                     | CN 1308527 T               | 15-08-2001          |
|   |   |                     | CZ 20010118 A3             | 13-06-2001          |
|   |   |                     | WO 0002539 A1              | 20-01-2000          |
|   |   |                     | EP 1094796 A1              | 02-05-2001          |
|   |   |                     | HU 0103715 A2              | 29-05-2002          |
|   |   |                     | JP 2002520270 T            | 09-07-2002          |
|   |   |                     | NZ 509216 A                | 26-07-2002          |
|   |   |                     | PL 345535 A1               | 17-12-2001          |
|   |   |                     | TR 200100022 T2            | 21-05-2001          |
| WO 0180797                                | A | 01-11-2001          | US 6313370 B1              | 06-11-2001          |
|   |   |                     | AU 5921201 A               | 07-11-2001          |
|   |   |                     | WO 0180797 A1              | 01-11-2001          |
| WO 9822114                                | A | 28-05-1998          | AU 4941297 A               | 10-06-1998          |
|   |   |                     | WO 9822114 A1              | 28-05-1998          |
| US 5719197                                | A | 17-02-1998          | US 5446070 A               | 29-08-1995          |
|   |   |                     | US 5234957 A               | 10-08-1993          |
|   |   |                     | US 5686099 A               | 11-11-1997          |
|   |   |                     | US 5300291 A               | 05-04-1994          |
|   |   |                     | US 4994267 A               | 19-02-1991          |
|   |   |                     | US 4814168 A               | 21-03-1989          |
|   |   |                     | AU 6029096 A               | 30-12-1996          |
|   |   |                     | WO 9640086 A2              | 19-12-1996          |
|   |   |                     | ZA 9604735 A               | 19-12-1996          |
|   |   |                     | AU 7672294 A               | 21-03-1995          |
|   |   |                     | CA 2170504 A1              | 02-03-1995          |
|   |   |                     | WO 9505813 A1              | 02-03-1995          |
|   |   |                     | WO 9640084 A1              | 19-12-1996          |
|   |   |                     | WO 9606602 A1              | 07-03-1996          |
|   |   |                     | AT 144704 T                | 15-11-1996          |
|   |   |                     | AU 658870 B2               | 04-05-1995          |
|   |   |                     | AU 1461092 A               | 06-10-1992          |
|   |   |                     | CA 2104474 A1              | 28-08-1992          |
|   |   |                     | DE 69214938 D1             | 05-12-1996          |
|   |   |                     | DE 69214938 T2             | 15-05-1997          |
|   |   |                     | DK 573576 T3               | 01-04-1997          |
|   |   |                     | EP 0573576 A1              | 15-12-1993          |
|   |   |                     | EP 0728477 A2              | 28-08-1996          |
|   |   |                     | ES 2094906 T3              | 01-02-1997          |
|   |   |                     | FI 933761 A                | 26-08-1993          |
|   |   |                     | GR 3022708 T3              | 31-05-1997          |
|   |   |                     | JP 6508820 T               | 06-10-1994          |
|   |   |                     | NO 933296 A                | 01-11-1993          |
|   |   |                     | SG 49158 A1                | 18-05-1998          |
|   |   |                     | SG 77626 A1                | 16-01-2001          |
|   |   |                     | US 5332576 A               | 26-07-1994          |
|   |   |                     | WO 9215289 A1              | 17-09-1992          |
|   |   |                     | AU 694243 B2               | 16-07-1998          |
|   |   |                     | AU 2833195 A               | 28-09-1995          |
|   |   |                     | US 5656286 A               | 12-08-1997          |
|   |   |                     | US 5958446 A               | 28-09-1999          |



INTERNATIONAL SEARCH REPORT  
Information on patent family members

International Application No  
PCT/UK 02/00884

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US 5719197 A                              |                     | US 5474783 A               | 12-12-1995          |
|   |                     | US 6024976 A               | 15-02-2000          |
|   |                     | AT 122240 T                | 15-05-1995          |
|   |                     | AU 632534 B2               | 07-01-1993          |
|   |                     | AU 5034990 A               | 13-08-1990          |
|   |                     | CA 2044132 A1              | 12-07-1990          |
|   |                     | DE 69019175 D1             | 14-06-1995          |
|   |                     | DE 69019175 T2             | 18-01-1996          |
|   |                     | DK 379045 T3               | 09-10-1995          |
|   |                     | EP 0379045 A1              | 25-07-1990          |
|   |                     | EP 0453505 A1              | 30-10-1991          |
|   |                     | EP 0634179 A1              | 18-01-1995          |
|   |                     | ES 2071683 T3              | 01-07-1995          |
|   |                     | HK 1006155 A1              | 12-02-1999          |
| US 6190690 B1                             | 20-02-2001          | KR 213465 B1               | 02-08-1999          |
|   |                     | DE 19728279 A1             | 08-01-1998          |
|   |                     | JP 10072343 A              | 17-03-1998          |
| US 6312713 B1                             | 06-11-2001          | NONE                       |                     |
| GB 2311027 A                              | 17-09-1997          | AT 220928 T                | 15-08-2002          |
|   |                     | AU 709420 B2               | 26-08-1999          |
|   |                     | AU 2102097 A               | 10-10-1997          |
|   |                     | CA 2248848 A1              | 25-09-1997          |
|   |                     | DE 69714226 D1             | 29-08-2002          |
|   |                     | DE 69714226 T2             | 23-01-2003          |
|   |                     | EP 0888140 A1              | 07-01-1999          |
|   |                     | WO 9734645 A1              | 25-09-1997          |
|   |                     | JP 2000506760 T            | 06-06-2000          |
| US 5792469 A                              | 11-08-1998          | US 5725491 A               | 10-03-1998          |
|   |                     | US 5632727 A               | 27-05-1997          |
|   |                     | AU 3117493 A               | 16-09-1993          |
|   |                     | CA 2091552 A1              | 13-09-1993          |
|   |                     | EP 0560014 A1              | 15-09-1993          |
|   |                     | JP 6007423 A               | 18-01-1994          |
| US 5993849 A                              | 30-11-1999          | DE 19653606 A1             | 25-06-1998          |
|   |                     | DE 59708373 D1             | 07-11-2002          |
|   |                     | EP 0848950 A2              | 24-06-1998          |
|   |                     | JP 10182440 A              | 07-07-1998          |